Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

113 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Comment on: Does the number of nodes removed impact survival in vulvar cancer patients with node-negative disease? Madeleine Courtney-Brooks, Paniti Sukumvanich, Sushil Beriwal, Kristin K. Zorn, Scott D. Richard, Thomas C. Krivak. Gynecological Oncology 117 (2010) 308-311.
van Beekhuizen HJ, van Doorn HC. van Beekhuizen HJ, et al. Among authors: van doorn hc. Gynecol Oncol. 2011 Jan;120(1):160; author reply 160-1. doi: 10.1016/j.ygyno.2010.09.020. Epub 2010 Nov 1. Gynecol Oncol. 2011. PMID: 21040951 No abstract available.
Long-term results of weekly paclitaxel carboplatin induction therapy: an effective and well-tolerated treatment in patients with platinum-resistant ovarian cancer.
van der Burg ME, Vergote I, Onstenk W, Boere IA, Leunen K, van Montfort CA, van Doorn HC. van der Burg ME, et al. Among authors: van montfort ca, van doorn hc. Eur J Cancer. 2013 Apr;49(6):1254-63. doi: 10.1016/j.ejca.2012.11.027. Epub 2012 Dec 29. Eur J Cancer. 2013. PMID: 23276720 Clinical Trial.
Long-term results of a randomised phase III trial of weekly versus three-weekly paclitaxel/platinum induction therapy followed by standard or extended three-weekly paclitaxel/platinum in European patients with advanced epithelial ovarian cancer.
van der Burg ME, Onstenk W, Boere IA, Look M, Ottevanger PB, de Gooyer D, Kerkhofs LG, Valster FA, Ruit JB, van Reisen AG, Goey SH, van der Torren AM, ten Bokkel Huinink D, Kok TC, Verweij J, van Doorn HC. van der Burg ME, et al. Among authors: van reisen ag, van doorn hc, van der torren am. Eur J Cancer. 2014 Oct;50(15):2592-601. doi: 10.1016/j.ejca.2014.07.015. Epub 2014 Aug 2. Eur J Cancer. 2014. PMID: 25096168 Clinical Trial.
Relevance of routine pathology review in cervical carcinoma.
van Beekhuizen HJ, Freulings MD, Dasgupta S, van Kemenade FJ, Ewing-Graham PC, van Doorn HC. van Beekhuizen HJ, et al. Among authors: van kemenade fj, van doorn hc. Virchows Arch. 2020 Aug;477(2):301-307. doi: 10.1007/s00428-019-02743-1. Epub 2020 Jan 9. Virchows Arch. 2020. PMID: 31919628
113 results